Lipella PharmaceuticalsLIPO
13F holders, Q1 2025 (March 31)3holders
1new positions
1sold out
$2.51avg. 13F price*
At the end of Q1 2025, 3 institutions reported holding Lipella Pharmaceuticals Inc. (LIPO) in their 13F filings, unchanged from Q4 2024. 1 opened new positions and 1 sold out. The largest holders were Tower Research Capital LLC (TRC) ($7K), MAI Capital Management ($314) and Bank of America Corp. ($18).
- Company
- Lipella Pharmaceuticals Inc.
- CUSIP
- 53630L209
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $7K |
| Exits | 1 | $41K |
All 13F filers, Q4 2024 → Q1 2025: 2,708 shares bought and 13,310 shares sold, net −10,602 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Tower Research Capital LLC (TRC) | 0.00% | New | 2,708 | $7K |
| MAI Capital Management | 0.00% | No change | 125 | $314 |
| Bank of America Corp. | 0.00% | No change | 7 | $18 |
"% of holder's portfolio" is LIPO's weight in each manager's 13F, not the share of Lipella Pharmaceuticals Inc. the manager owns.